Halozyme Therapeutics, Inc.
HALO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001159036
In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 674 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Halozyme Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 637 | 6 | 674 | +43 |
| Shares | 120.5M | 1.27M | 123.3M | +4.08M (+3.4%) |
| Value | $7.79B | $82.1M | $9.62B | +$1.91B (+24.9%) |
6 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (109)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
Showing the largest 100 of 109 by value.
Sold out (66)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
Not filed for Q2 2026 yet (6)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Janus Henderson Group PLC | 1,233,658 | $79.7M |
| Skopos Labs, Inc. | 10,833 | $700.1K |
| CWM, LLC | 10,303 | $665.9K |
| Gibbs Wealth Management | 9,049 | $584.8K |
| Jaffetilchin Investment Partners, LLC | 6,145 | $397.2K |
| USA Financial Portformulas Corp | 13 | $840 |